Sign In
Buy LIVN
$80.14
-0.91 (-1.12%)
At Close: Jul 31, 2026
LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints
04:05pm, Monday, 11'th Nov 2024
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.
LivaNova (LIVN) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:00pm, Thursday, 07'th Nov 2024
LivaNova (LIVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
How Much Upside is Left in LivaNova (LIVN)? Wall Street Analysts Think 38.2%
11:00am, Thursday, 07'th Nov 2024
The consensus price target hints at a 38.2% upside potential for LivaNova (LIVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Best Momentum Stocks to Buy for November 7th
11:00am, Thursday, 07'th Nov 2024
KRUS, FTDR and LIVN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 7, 2024.
New Strong Buy Stocks for November 7th
06:31am, Thursday, 07'th Nov 2024
MCO, EBS, LIVN, FTDR and KRUS have been added to the Zacks Rank #1 (Strong Buy) List on November 7, 2024.
Best Value Stocks to Buy for November 7th
05:40am, Thursday, 07'th Nov 2024
JWN and LIVN made it to the Zacks Rank #1 (Strong Buy) value stocks list on November 7, 2024.
LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript
02:30pm, Wednesday, 30'th Oct 2024
LivaNova PLC (NASDAQ:LIVN ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President-Corporate Development & IT Vladimir Makatsaria - Chi
LivaNova (LIVN) Tops Q3 Earnings and Revenue Estimates
08:15am, Wednesday, 30'th Oct 2024
LivaNova (LIVN) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.73 per share a year ago.
LivaNova Reports Third-Quarter 2024 Results
06:00am, Wednesday, 30'th Oct 2024
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance.
LivaNova: Economics Should Start Making Sustained Improvements
03:45am, Friday, 18'th Oct 2024
LivaNova's Essenz product drives revenue growth, with successful rollout and premium pricing boosting guidance despite tough comparisons into the end of the year. Neuromodulation revenues, particularl
LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts
11:59am, Friday, 04'th Oct 2024
Shares of LivaNova Plc LIVN Tuesday climbed along with several other big stocks.
LivaNova PLC (LIVN) Q2 2024 Earnings Call Transcript
01:57pm, Wednesday, 31'st Jul 2024
LivaNova PLC (NASDAQ:LIVN ) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Matthew Dodds – Senior Vice President-Corporate Development and IT Vladimir Makatsaria –
LivaNova (LIVN) Beats Q2 Earnings and Revenue Estimates
08:10am, Wednesday, 31'st Jul 2024
LivaNova (LIVN) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.78 per share a year ago.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN
12:19pm, Friday, 26'th Jul 2024
NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC (“LivaNova” or the “Company”) (NASDAQ: LIVN). Such investors are advi
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN
08:57pm, Wednesday, 24'th Jul 2024
NEW YORK , July 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC ("LivaNova" or the "Company") (NASDAQ: LIVN). Such investors are advised to cont
